| Donor . | Age . | Sex . | Cause of death . | Length of stay . | EBV IgG . | CMV IgG . | CMV IgG aviditya . | CMV IgMb . | HLA type . | CMV-multimer detectedc . |
|---|---|---|---|---|---|---|---|---|---|---|
| yr | d | |||||||||
| 201 | 21 | M | HT | 7 | + | + | High | − | A2, B7 | Yes |
| 146 | 23 | F | HT | 5 | + | + | ND | ND | A2 | Yes |
| 207 | 23 | M | HT | 7 | + | + | High | − | A2 | Yes |
| 103 | 25 | M | HT | 7 | + | + | High | − | A3, B35 | Yes |
| 227 | 26 | M | HT | 20 | + | + | High | − | A3 | Yes |
| 204 | 30 | M | CVA | 3 | + | + | Low | − | A3 | No |
| 169 | 33 | M | HT | 3 | ND | + | ND | ND | A3, A24 | Yes |
| 216 | 34 | M | HT | 6 | + | + | ND | ND | A2 | Yes |
| 174 | 35 | F | A | 7 | + | + | ND | ND | A3, B7 | Yes |
| 147 | 36 | F | CVA | 10 | + | + | ND | ND | A2, A24 | Yes |
| 195 | 37 | F | CVA | 4 | + | + | I | − | A2, B35 | No |
| 150 | 39 | M | CVA | 5 | + | + | High | − | A24, B35 | Yes |
| 156 | 40 | F | CVA | 5 | + | + | ND | ND | A2, A24 | Yes |
| 196 | 45 | F | CVA | 9 | + | + | High | − | A2 | Yes |
| 172 | 49 | M | A | 6 | + | + | High | − | A24, A68, B7 | Yes |
| 217 | 49 | M | A | 5 | + | + | High | − | A68, B7 | Yes |
| 199 | 50 | M | CVA | 15 | + | + | High | − | A2, A3 | Yes |
| 194 | 53 | M | CVA | 12 | + | + | High | − | A24, B7 | Yes |
| 208 | 54 | M | A | 5 | + | + | I | − | A3, A24, B7 | Yes |
| 225 | 54 | M | CVA | 5 | − | + | High | − | A24 | No |
| 220 | 64 | M | A | 3 | + | + | High | − | A2, A24 | Yes |
| 226 | 66 | F | HT | 4 | + | + | ND | ND | A1, A3, B35 | Yes |
| 190 | 69 | F | CVA | 5 | + | + | I | − | A68 | No |
| 197 | 70 | F | A | 8 | + | + | ND | ND | A1 | Yes |
| 143 | 6 | M | CVA | 2 | + | − | ND | ND | A2, A3, B7 | No |
| 105 | 20 | M | HT | 11 | + | − | ND | ND | A2, A24 | No |
| 86 | 24 | F | HT | 11 | + | − | ND | ND | A24 | No |
| 84 | 31 | F | A | 3 | + | − | ND | ND | A1, A2, B35 | No |
| 39 | 32 | M | NA | NA | + | − | ND | ND | A3 | No |
| 48 | 35 | M | HT | 3 | + | − | ND | ND | B35 | No |
| 83 | 41 | M | CVA | 9 | + | − | ND | ND | A2, B7 | No |
| 81 | 43 | M | CVA | 2 | + | − | ND | ND | A2, B7 | No |
| 212 | 48 | M | NA | NA | + | − | ND | ND | A2, B7 | No |
| 193 | 50 | M | A | 23 | + | − | ND | ND | A24 | No |
| 202 | 50 | M | CVA | 6 | + | − | ND | ND | A3, B7 | No |
| 206 | 50 | M | CVA | 8 | + | − | ND | ND | A1 | No |
| 177 | 52 | F | CVA | 3 | + | − | ND | ND | A2 | No |
| 200 | 55 | M | CVA | 7 | + | − | ND | ND | A2, B7 | No |
| 111 | 58 | M | CVA | 3 | + | − | ND | ND | A1, A2 | No |
| 209 | 59 | M | CVA | 4 | + | − | ND | ND | A2 | No |
| 65 | 69 | M | CVA | 6 | + | − | ND | ND | A68 | No |
| Donor . | Age . | Sex . | Cause of death . | Length of stay . | EBV IgG . | CMV IgG . | CMV IgG aviditya . | CMV IgMb . | HLA type . | CMV-multimer detectedc . |
|---|---|---|---|---|---|---|---|---|---|---|
| yr | d | |||||||||
| 201 | 21 | M | HT | 7 | + | + | High | − | A2, B7 | Yes |
| 146 | 23 | F | HT | 5 | + | + | ND | ND | A2 | Yes |
| 207 | 23 | M | HT | 7 | + | + | High | − | A2 | Yes |
| 103 | 25 | M | HT | 7 | + | + | High | − | A3, B35 | Yes |
| 227 | 26 | M | HT | 20 | + | + | High | − | A3 | Yes |
| 204 | 30 | M | CVA | 3 | + | + | Low | − | A3 | No |
| 169 | 33 | M | HT | 3 | ND | + | ND | ND | A3, A24 | Yes |
| 216 | 34 | M | HT | 6 | + | + | ND | ND | A2 | Yes |
| 174 | 35 | F | A | 7 | + | + | ND | ND | A3, B7 | Yes |
| 147 | 36 | F | CVA | 10 | + | + | ND | ND | A2, A24 | Yes |
| 195 | 37 | F | CVA | 4 | + | + | I | − | A2, B35 | No |
| 150 | 39 | M | CVA | 5 | + | + | High | − | A24, B35 | Yes |
| 156 | 40 | F | CVA | 5 | + | + | ND | ND | A2, A24 | Yes |
| 196 | 45 | F | CVA | 9 | + | + | High | − | A2 | Yes |
| 172 | 49 | M | A | 6 | + | + | High | − | A24, A68, B7 | Yes |
| 217 | 49 | M | A | 5 | + | + | High | − | A68, B7 | Yes |
| 199 | 50 | M | CVA | 15 | + | + | High | − | A2, A3 | Yes |
| 194 | 53 | M | CVA | 12 | + | + | High | − | A24, B7 | Yes |
| 208 | 54 | M | A | 5 | + | + | I | − | A3, A24, B7 | Yes |
| 225 | 54 | M | CVA | 5 | − | + | High | − | A24 | No |
| 220 | 64 | M | A | 3 | + | + | High | − | A2, A24 | Yes |
| 226 | 66 | F | HT | 4 | + | + | ND | ND | A1, A3, B35 | Yes |
| 190 | 69 | F | CVA | 5 | + | + | I | − | A68 | No |
| 197 | 70 | F | A | 8 | + | + | ND | ND | A1 | Yes |
| 143 | 6 | M | CVA | 2 | + | − | ND | ND | A2, A3, B7 | No |
| 105 | 20 | M | HT | 11 | + | − | ND | ND | A2, A24 | No |
| 86 | 24 | F | HT | 11 | + | − | ND | ND | A24 | No |
| 84 | 31 | F | A | 3 | + | − | ND | ND | A1, A2, B35 | No |
| 39 | 32 | M | NA | NA | + | − | ND | ND | A3 | No |
| 48 | 35 | M | HT | 3 | + | − | ND | ND | B35 | No |
| 83 | 41 | M | CVA | 9 | + | − | ND | ND | A2, B7 | No |
| 81 | 43 | M | CVA | 2 | + | − | ND | ND | A2, B7 | No |
| 212 | 48 | M | NA | NA | + | − | ND | ND | A2, B7 | No |
| 193 | 50 | M | A | 23 | + | − | ND | ND | A24 | No |
| 202 | 50 | M | CVA | 6 | + | − | ND | ND | A3, B7 | No |
| 206 | 50 | M | CVA | 8 | + | − | ND | ND | A1 | No |
| 177 | 52 | F | CVA | 3 | + | − | ND | ND | A2 | No |
| 200 | 55 | M | CVA | 7 | + | − | ND | ND | A2, B7 | No |
| 111 | 58 | M | CVA | 3 | + | − | ND | ND | A1, A2 | No |
| 209 | 59 | M | CVA | 4 | + | − | ND | ND | A2 | No |
| 65 | 69 | M | CVA | 6 | + | − | ND | ND | A68 | No |
−, negative; +, positive; NA, not available; ND, not done; F, female; HLA, human leukocyte antigen; M, male.
CMV IgG avidity index reference ranges: High (≥0.60), intermediate (0.51–0.59), low (≤0.50).
CMV IgM reference range: Negative (≤0.80), equivocal (0.9–1.0), positive (≥1.1).
CMV-multimer detected is defined as >0.1–0.3% of CD8+ T cells where >500 CD8+ T cells were available.